Overview
A postdoctoral position is available in the laboratory of Gordon Freeman in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School. The lab focuses on costimulatory and coinhibitory pathways, particularly the PD-L1/PD-1 and HHLA2/KIR3DL3 pathways.Located in Boston and the surrounding communities, Dana-Farber Cancer Institute is a leader in life changing breakthroughs in cancer research and patient care. We are united in our mission of conquering cancer, HIV/AIDS, and related diseases. We strive to create an inclusive, diverse, and equitable environment where we provide compassionate and comprehensive care to patients of all backgrounds, and design programs to promote public health particularly among high-risk and underserved populations. We conduct groundbreaking research that advances treatment, we educate tomorrow's physician/researchers, and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
This position will involve examining the role of PD-1 and other coinhibitory pathways in immune responses and particularly on therapeutic synergies of coinhibitory blockade for anti-tumor immunity.
With a career at Dana-Farber Cancer Institute, you play an important role in helping to fulfill our mission and ultimate goal: the eradication of cancer and related diseases. We are ranked as one of the nation's best midsize employers and offer exciting jobs and careers to match your skills, interests, and passions.
The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases.
As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world.
